Hope for Gastric Lesions Through EP4 Agonist

by Rajshri on  November 20, 2009 at 8:44 PM Research News
  •   Print
  •   Share
  •   Comments
  •  Text 
One of the widely used medication for treating pain, arthritis, fever and other diseases is a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs), which are used by over 300 million people across the globe..

Nearly 30% of the users suffer from gastric lesions and bleeding. To mitigate NSAIDs' adverse effects on the stomach, misoprostol, a non-selective prostaglandin E1 (PGE1) analogue, has been prescribed as the first choice for prevention of NSAID-induced injuries, but often induces severe adverse effects. There remain unmet medical needs for drugs with improved therapeutic profiles.

A research article published on November 7, 2009 in the World Journal of Gastroenterology addresses this question. A research team from United States investigated therapeutic potentials of a highly-selective EP4 agonist for treatment of a mouse gastric ulcer model in the presence or absence of indomethacin at various levels.

They found the EP4-selective agonist reduced high dose indomethacin-induced acute hemorrhagic damage and promoted mucous epithelial regeneration. Low-dose indomethacin aggravated ulcer bleeding and inflammation, and delayed the healing of the established chronic gastric ulcer. The EP4 agonist, when applied locally, not only offset indomethacin-induced gastric bleeding and inflammation, but also accelerated ulcer healing. In the absence of indomethacin, the EP4 agonist even accelerated chronic gastric ulcer healing and suppressed inflammatory cell infiltration in the granulation tissue. In vitro, the EP4 agonist protected human gastric mucous cells from indomethacin-induced apoptosis.

Their results suggest that EP4 agonists may mimic the gastric protective effects of PGE2 in the presence or absence of NSAIDs, and may show advantages over non-selective analogs such as misoprostol by minimizing adverse effects arising from activating all 4 subtype receptors of PGE2.



Source-Eurekalert
RAS

 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
Gastric
Complete Medindia Resources
News Categories:  
Teen's Health Center

Research Related News

» New Drug That Only Attacks Cancer Cells Developed » Personality Traits Linked To Longevity in Centenarians
» Lack of Vitamin D in Diet Raises Stroke Risk in Japanese-Americans » Why Bovine TB Continues to Spread Demystified in New Research
» Seaweed Pill May Help Treat Arthritis » P. Aeruginosa Infection Leads to Worse Outcomes and Increased Hospitalizations in COPD Patients
» Hormone Boosts Production of Molecules Which Fight Skin Infection » Protein Discovery Could Lead To New Vaccine for Meningitis
Read More >>